Amylyx Pharmaceuticals, Inc. (AMLX) vs AMNEAL PHARMACEUTICALS, INC. (AMRX)
Amylyx Pharmaceuticals, Inc. and AMNEAL PHARMACEUTICALS, INC. are both Drug Manufacturers Specialty & Generic companies. AMNEAL PHARMACEUTICALS, INC. is the larger, with a market value of $6.3B against $3.8B — 1.7× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; AMNEAL PHARMACEUTICALS, INC. trades at 39.5×. AMNEAL PHARMACEUTICALS, INC. grew revenue faster over the last twelve months: 9.28% against −77.1%. AMNEAL PHARMACEUTICALS, INC. has the higher net margin (5.05% vs 0.00%) and the higher return on invested capital (11.1% vs 0.00%). Across the 18 metrics below, AMNEAL PHARMACEUTICALS, INC. leads on 11 and Amylyx Pharmaceuticals, Inc. on 7.
Valuation
Profitability
| Metric | AMLX | AMRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 39.32% | 53.94% |
| Operating margin | 0.00% | 14.56% | 0.00% |
| Net margin | 0.00% | 5.05% | 0.00% |
| Free cash flow margin | 0.00% | (0.37%) | 0.00% |
| Return on equity | (74.73%) | (395.84%) | (0.40%) |
| Return on assets | (66.25%) | 4.37% | (3.32%) |
| Return on invested capital | 0.00% | 11.05% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack